Insider filing
Traded Oct 15 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 30, 2026 · Filed Oct 1, 2026
The CEO of Xenon Pharmaceuticals paid $1.12M out of pocket for Xenon Pharmaceuticals shares. 1 other person at Xenon Pharmaceuticals bought some too, in the same month. Shares held went up 151% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$1,121,400
Shares × reported transaction price
$1M+
+150.6%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 12% of the CEO's reported total pay for fiscal 2025 ($9.22M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-22. The proxy names Mr. Mortimer as CEO for that year. A size comparison, not a judgement
55 days after results of Aug 6, 2026, 40 days before results of Nov 9, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $37.19 on Sep 30, 2026, within 2% of its 52-week low, after a 40% drop over the previous 30 trading days
52-week range $36.56 (Sep 23, 2026) to $70.96 (Jul 9, 2026), 2% of the way up, from 250 adjusted closes. 30 trading days earlier: $62.36 on Aug 17, 2026. Describes the past only, not a forecast
RSI 19, 30% under its 200-day average, 36% under its 50-day average, 48% below the 52-week high, 20-day volatility 132% a year, against the S&P 500: −37 points over 1 month, −41 points over 3 months, −54 points over 6 months
From the adjusted closes up to Sep 30, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The largest open-market purchase by any XENE insider in filings since 2015. The first open-market purchase by any XENE insider since Jan 2022. Ian Mortimer's largest purchase of XENE in their filings since 2016
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.2% | +1.2% | −5.3% |
| 30 days | −1.1% | −2.3% | +1.2% |
Past results only. Not a forecast.
Insider filing
Traded Oct 15 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Oct 15 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider buying
Largest insider buy since 2015Traded Sep 30 · filed 1 day later
The CFO of Xenon Pharmaceuticals paid $560K out of pocket for Xenon Pharmaceuticals shares. 1 other person at Xenon Pharmaceuticals bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.